Randomised trial of intradermal Mycobacterium vaccae or intradermal hepatitis B immunisation in children with HIV infection.
This study assessed the safety of inactivated Mycobacterium vaccae as a candidate vaccine to prevent disseminated mycobacterial disease in children with HIV infection. 35 children ages 1-8 with CD4 counts > or =300/mm3 in New Hampshire, Boston and Chicago were randomised in a 2:1 schedule to receive a 3-dose series of intradermal M. vaccae vaccine (MV) or hepatitis B vaccine (HBV) at 2-month intervals. Immunisation was safe and well tolerated; 2-day median vaccine site in duration was 5 mm in MV recipients and 0 mm in HBV recipients (p < 0.001). There were no significantly different changes in viral load or CD4 count between the two vaccine groups. No PPD skin test conversions occurred after immunisation. MV is safe and well tolerated and deserves further evaluation as a vaccine to prevent mycobacterial disease in HIV-infected children.
Johnson
D
D
Section of Paediatric Infectious Diseases, University of Chicago Children's Hospital, IL, USA.
Waddell
R D
RD
Pelton
S I
SI
Jaeger
A S
AS
Modlin
J F
JF
Yogev
R
R
Morin
P
P
Arbeit
R D
RD
von Reyn
C F
CF
D000279:Administration, Cutaneous; D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood; D001428:Bacterial Vaccines / Q000276:immunology*; D018791:CD4 Lymphocyte Count; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D015658:HIV Infections / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007223:Infant; D008213:Lymphocyte Activation; D009161:Mycobacterium / Q000276:immunology*; D012882:Skin Tests
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines